Common questions about Vumerity (FAQ)
Q: Is Vumerity considered a chemotherapy drug?
A: Vumerity is classified by regulatory bodies as an immunomodulator and a fumaric acid derivative. Its official classification does not identify it as a chemotherapy drug. The medicine is intended to influence certain parts of the immune system.
Q: Do you have to take Vumerity for the rest of your life?
A: Vumerity is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Since MS is typically managed as a chronic, long-term condition, the medicine is designed for long-term therapy to help manage sustained immune activity. The duration of treatment is determined as part of the management plan for MS.
Q: Can Vumerity cure multiple sclerosis?
A: According to the official product information, Vumerity is approved to treat relapsing forms of multiple sclerosis. Regulatory documents do not state that Vumerity is a cure for multiple sclerosis. MS medicines are generally used to help manage the disease and reduce the frequency of relapse.
Q: Does Vumerity cause hair loss?
A: Hair loss (alopecia) has been reported in postmarketing experience with the active ingredient found in Vumerity. Official regulatory documents note these reports, but a definite cause-and-effect relationship has not been established in the official data.
Q: Does Vumerity make you feel tired or fatigued?
A: Tiredness or fatigue is not listed as a common or very common side effect in the core prescribing information. However, regulatory patient information lists severe tiredness or severe fatigue as a symptom that may indicate a serious liver problem, which is a risk monitored periodically during treatment.
Q: Are there any long-term side effects of Vumerity that people should know about?
A: Studies and official information indicate the need to monitor for Prolonged Severe Lymphopenia, which is a very low white blood cell count persisting for more than six months. Lymphocyte counts typically decrease during the first year of treatment and then generally remain stable. This low count may be linked to the risk of serious infections and is a risk monitored periodically during treatment.
Q: Can Vumerity be used by people over the age of 65?
A: Vumerity is indicated for use in adult patients. However, official regulatory data regarding its use is limited for older adults aged 65 years and over.
Q: Are there different dosages of Vumerity available?
A: Official regulatory documents define a starting dosage for the first 7 days, followed by a standard maintenance dosage thereafter. A temporary change in dose may be described for patients who experience issues tolerating the standard maintenance dose.
Q: What happens if you miss a dose of Vumerity?
A: If a dose is missed, regulatory patient information generally advises to take the missed dose as soon as possible. If it is almost time for the next dose, the patient should skip the missed dose and resume their regular schedule. Regulatory patient information advises against taking two doses at once to make up for a missed dose.
Q: Does Vumerity need to be kept refrigerated?
A: No. Official regulatory storage instructions state that the medicine must be kept at room temperature, specifically between 68 F and 77 F (20 C and 25 C). It is explicitly advised not to refrigerate or freeze the capsules.
Q: Can Vumerity cause issues with my kidneys?
A: Vumerity is not recommended for use in patients who already have moderate or severe renal impairment (kidney function problems). This restriction is due to an increase in systemic exposure to a major inactive metabolite in this population. In clinical trials, the presence of albumin in the urine was reported as a side effect.
Q: What are the signs of a serious allergic reaction to Vumerity?
A: Regulatory safety information identifies signs of a serious hypersensitivity reaction, such as anaphylaxis or angioedema. These signs may include difficulty breathing, the development of hives (urticaria), or swelling of the throat and tongue.
Q: Is it okay to drink alcohol while on Vumerity?
A: Regulatory labeling advises patients to avoid co-administration of Vumerity with alcohol at the time of the dose. Consuming alcohol near the time of dosing may reduce the peak concentration of the active substance that is absorbed by the body.
Q: What kind of studies were done to get Vumerity approved?
A: Regulatory approval was supported by bioequivalence studies which demonstrated Vumerity delivered the same amount of the active substance to the body as a related compound. A short-term randomized study also evaluated tolerability, with core efficacy evidence based on linking to existing large-scale trials.
Q: Is there a generic version of Vumerity available?
A: The FDA has approved a generic version of the medicine's active ingredient (diroximel fumarate). The availability of any generic product in pharmacies depends on the status of patents and exclusivity rights.
Q: Do you need a special diet when taking Vumerity?
A: Regulatory documents do not require a general 'special diet' while taking Vumerity. The only documented restriction is to avoid high-fat, high-calorie meals or snacks (over 700 calories or 30 grams of fat) at the time of the dose, as this may reduce drug absorption.
Q: Can Vumerity be taken during pregnancy?
A: There are no adequate human data on the developmental risk associated with the use of Vumerity in pregnant women. Official regulatory documents indicate that the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Q: Has Vumerity been studied in children or teenagers?
A: The medicine is not approved for use in individuals under 18 years old. Regulatory documents indicate that the safety and effectiveness have not been established in pediatric patients in official studies.
Q: Can Vumerity affect fertility in women or men?
A: Official regulatory documents do not contain specific human data regarding the effect of Vumerity on fertility in women or men. While animal studies have shown adverse effects on sperm parameters, the relevance of these findings to human fertility is uncertain.
Q: Does Vumerity cause headaches or dizziness?
A: Headaches and dizziness are sometimes listed as potential side effects in patient-facing regulatory materials. These effects are not typically classified as 'Very Common' or 'Common' in the main frequency tables of the core prescribing information.
Q: What is the risk of PML with Vumerity?
A: PML (Progressive Multifocal Leukoencephalopathy) is a rare, opportunistic viral infection of the brain that has occurred in patients treated with the related compound (dimethyl fumarate). Regulatory documents state that the risk is mainly linked to patients who have developed prolonged low white blood cell counts (lymphocyte counts) for more than six months.
Q: What if I get sick with a cold or flu while taking Vumerity?
A: Due to its immune-modulating properties, Vumerity may increase the risk of serious infections. Regulatory documents advise considering withholding Vumerity in cases of serious infection until the infection has resolved.
Q: Can Vumerity affect your liver function?
A: Yes, official safety information notes that Vumerity can cause liver injury. Elevations in certain liver enzymes are classified as a Common side effect, and drug-induced liver injury is listed as a rare but serious adverse reaction that has been observed.
